news

Report: US vaccine shows strong immune response to coronavirus in clinical trials

WASHINGTON (Sept 26): The US pharmaceutical and medical device company Johnson and Johnson has developed a vaccine that in the early trials showed a strong immune response to the novel coronavirus with a single dose, according to Sputnik News Agency quoting an interim report published on the medical website medRxiv.         

"The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against Covid-19," said the report. 

"A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients."          

The Johnson and Johnson vaccine is the fourth in the United States to enter the final phase of clinical trials. 

President Donald Trump has promised that 100 million doses of a vaccine will be distributed throughout the United States by the end of the year. Trump said a vaccine could be available for distribution before the presidential election on Nov 3. 

Get the latest news @ www.EdgeProp.my

Click here for more property stories.

Looking for properties to buy or rent? With >150,000 exclusive listings, including undervalued properties, from vetted Pro Agents, you can now easily find the right property on Malaysia's leading property portal EdgeProp! You can also get free past transacted data and use our proprietary Edge Reference Price tool, to make an informed purchase.
SHARE
RELATED POSTS
  1. Malaysia-Singapore border opening delayed due to spike in Covid-19 cases
  2. Malaysia's Covid-19 vaccine first recipients not 'lab rats' — PM Muhyiddin
  3. Covid-19: Travellers from Sabah to Kelantan must undergo second swab test